[Skip to Navigation]
December 1978

Fate of Pemphigus Antibody Following Successful Therapy: Preliminary Evaluation of Pemphigus Antibody Determinations to Regulate Therapy

Author Affiliations

From the Department of Dermatology, State University of New York at Buffalo (Drs O'Loughlin and Provost). Dr Goldman is in private practice in St Petersburg, Fla. Dr Provost is currently with the Department of Dermatology, Johns Hopkins School of Medicine, Good Samaritan Hospital, Baltimore.

Arch Dermatol. 1978;114(12):1769-1772. doi:10.1001/archderm.1978.01640240011003

• Six of 17 pemphigus patients (35%) treated during a six-year period with immunosuppressive agents and/or corticosteroids have had prolonged clinical and immunologic remissions off all therapy. All were treated until serum and tissue bound pemphigus antibodies could no longer be detected. The length of remission has ranged from 1½ years to 4 years. Three of these six patients relapsed after being clinically and serologically free of pemphigus for 19, 20, and 48 months. Seven additional patients are clinically free of disease with insignificant pemphigus antibody titers of 10 or less. Therapy now is being discontinued gradually in these patients.

This preliminary study demonstrates that (1) a large percentage of pemphigus patients may have a prolonged clinical and immunological remission after successful therapy; (2) maintenance therapy may not be required to preserve the remission; (3) monitoring serum and in vivo bound pemphigus antibody is of value in regulating therapy in pemphigus patients.

(Arch Dermatol 114:1769-1772, 1978)